Janssen, Johnson & Johnson's Subsidiary Has Submitted FDA Supplemental Marketing Application For Rybrevant Plus Chemotherapy As First-line Treatment Of Locally Advanced Or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Janssen, a subsidiary of Johnson & Johnson, has submitted a supplemental marketing application to the FDA for Rybrevant plus chemotherapy as a first-line treatment for locally advanced or metastatic EGFR Exon 20 insertion mutation-positive non-small cell lung cancer.
August 25, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's subsidiary Janssen has submitted a supplemental marketing application to the FDA for Rybrevant. If approved, this could potentially increase JNJ's market share in the cancer treatment sector.
The news directly pertains to Johnson & Johnson as Janssen is its subsidiary. If the FDA approves the application, it could potentially increase JNJ's market share in the cancer treatment sector, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100